We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Edinburgh Worldwide Investment Trust Plc | EWI | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| -0.60 | -0.31% | 190.40 | 16:35:06 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 191.20 | 189.00 | 191.20 | 190.40 | 191.00 |
| Industry Sector |
|---|
| EQUITY INVESTMENT INSTRUMENTS |
| Top Posts |
|---|
Posted at 15/6/2023 20:34 by takeiteasy In the COVID tech recovery this shot up and this time around the NASDAQ is well up in 2023 and this part of the market heads ever lower. I looked at some comments today to understand the market conditions better to understand how someone else in this area of the market assessed things. I.e. when we will know there is any sort of recovery to come back in?BIOG trust update today... Macroeconomic factors rather than industry fundamentals continued to dominate portfolio performance during the fiscal year. The fiscal year began with weakness in the biotech sector in April and May 2022, driven by continued investor concerns about rising interest rates. Continued rate hikes by the U.S. Federal Reserve (the Fed) to combat inflation drove down share prices for unprofitable technology stocks broadly, including emerging biotech. Valuations for emerging biotech, which had reached 20-year lows, appeared to bottom out in May and June. In August, drug pricing legislation in the U.S. was passed as part of the Democrats' "Inflation Reduction Act". While the bill allows for limited drug price negotiation by Medicare starting in 2026, the provisions appear manageable for the industry and passage of the bill cleared a longstanding political overhang for the sector. By the end of September, the biotech sector had begun staging a recovery from depressed levels. In October, a disappointing round of earnings from large capitalization (cap) technology stocks like Amazon and Meta and growing recession concerns appeared to draw generalist inflows into the defensive pharmaceutical sector and large cap biotech. Large cap biotech outperformance continued in November, but small cap biotech began outperforming in December, and January 2023. Unfortunately, interest rate expectations became more hawkish in February when the U.S. announced a lower-than-expected unemployment rate and higher-than-expected inflation, sending small cap shares back down. In March, the unexpected failure of Silicon Valley Bank (SVB) had a particularly negative impact on small cap biotech, many of which were SVB clients. Even though absolute cash exposure to SVB for most biotech companies was minimal, renewed risk aversion due to the concerns over the banking system caused large cap biotech to significantly outperform small cap biotech. This trading dynamic had a particularly detrimental impact on the Company's relative performance versus the Benchmark, given that the Company is significantly overweight small cap names and underweight large cap names. The drawdown in March accounted for virtually all of the underperformance of the Company's NAV versus the Benchmark for the fiscal year. Encouragingly, the Company has seen a rebound in relative performance in April and May 2023, which we hope signals a more sustained recovery. dyor etc |
Posted at 06/5/2022 14:29 by campervan1 I was just watching the tumble weed blowing along on this board and I came across this on the ewi website. A long and interesting history, with links to James Bond!I for one will continue to hold on through this particular storm, "if necessary lashed to the wheel". |
Posted at 10/6/2020 16:49 by uapatel Poikka,Might want to watch this Ron Baron interview on CNBC regarding his view on Tesla and SpaceX. Both of which EWI and SMT hold. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
